Cancer Risks for BRCA1 and BRCA2 Mutation Carriers: Results From Prospective Analysis of EMBRACE
Nasim Mavaddat(MRC Epidemiology Unit), Rosalind A. Eeles(Royal Marsden NHS Foundation Trust), Zosia Miedzybrodzka(NHS Grampian), Julian Adlard(Chapel Allerton Hospital), Antonis C. Antoniou(Weatherford College), Louise Izatt(Guy's and St Thomas' NHS Foundation Trust), Douglas F. Easton(University of Cambridge), Lucy Side(Unknown), Marc Tischkowitz(University of Cambridge), Patrick J. Morrison(Belfast Health and Social Care Trust), Catherine Houghton(Ollscoil na Gaillimhe – University of Galway), Julian Barwell(London North West Healthcare NHS Trust), Jacqueline Eason(Nottingham University Hospitals NHS Trust), Michael J. Kennedy(University of Virginia), Alex Murray(University Medical Center Utrecht), Huw Dorkins(London North West Healthcare NHS Trust), D. Gareth Evans(Manchester Academic Health Science Centre), Helen Gregory(Nutrition Sciences (Belgium)), Emma McCann(University of Liverpool), Trevor Cole(Birmingham Women's Hospital), Mark T. Rogers, Alan Donaldson(University Hospitals Bristol NHS Foundation Trust), Lisa Walker(Oxford University Hospitals NHS Trust), Mary Porteous(University of Edinburgh), Fiona Douglas(University of Southern California), Radka Platte(University of Cambridge), Rosemarie Davidson(The Netherlands Cancer Institute), Carole Brewer(Royal Devon and Exeter Hospital), Susan Peock(Cancer Research UK), Elena Fineberg, Shirley Hodgson(St Thomas' Hospital), Debra Frost(University of Cambridge), Jackie Cook(Sheffield Children's Hospital), Diana Eccles(Princess Anne Hospital)
Cited by 946
Related Papers
DNA-Repair Defects and Olaparib in Metastatic Prostate Cancer
|New England Journal of Medicine|2015|2.2k
The evolutionary history of lethal metastatic prostate cancer
|Nature|2015|1.4k
Polygenic Risk Scores for Prediction of Breast Cancer and Breast Cancer Subtypes
|The American Journal of Human Genetics|2018|1.2k